BioNTech, Pfizer sic mRNA on the flu

BioNTech AG (Mainz, Germany) partnered with Pfizer Inc. (NYSE:PFE) to develop mRNA-based influenza vaccines, marking the biotech's first step toward building an R&D presence in infectious disease.

BioNTech will receive $120 million in upfront and in near-term research payments. It is also eligible for up to $305 million in milestones, plus double-digit tiered royalties. The biotech will conduct a first-in-human study and Pfizer will assume responsibility for development and commercialization thereafter...